Big-name investors have poured money into developing “liquid biopsies” — blood tests intended to diagnose early-stage cancer in asymptomatic patients.
But is a pan-cancer blood test clinically realistic? The jury’s still out, in part because each individual’s cancer is different, and certain tumors can be stunningly complex.
About the Author Reprints
